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Abstract
Chronic myelogenous leukemia (CML) is characterized by the
expression of the BCR-ABL tyrosine kinase, which results in
increased cell proliferation and inhibition of apoptosis. In this
study, we show in both BCR-ABL cells (Mo7e-p210 and BaF/3-
p210) and primary CML CD34+ cells that STI571 inhibition of
BCR-ABL tyrosine kinase activity results in a G1 cell cycle
arrest mediated by the PI3K pathway. This arrest is associated
with a nuclear accumulation of p27Kip1 and down-regulation
of cyclins D and E. As a result, there is a reduction of the
cyclin E/Cdk2 kinase activity and of the retinoblastoma
protein phosphorylation. By quantitative reverse transcrip-
tion-PCR we show that BCR-ABL/PI3K regulates the expres-
sion of p27Kip1 at the level of transcription. We further show
that BCR-ABL also regulates p27Kip1 protein levels by
increasing its degradation by the proteasome. This degrada-
tion depends on the ubiquitinylation of p27Kip1 by Skp2-
containing SFC complexes: silencing the expression of Skp2
with a small interfering RNA results in the accumulation of
p27Kip1. We also demonstrate that BCR-ABL cells show
transcriptional up-regulation of Skp2. Finally, expression of
a p27Kip1 mutant unable of being recognized by Skp2 results
in inhibition of proliferation of BCR-ABL cells, indicating that
the degradation of p27Kip1 contributes to the pathogenesis of
CML. In conclusion, these results suggest that BCR-ABL
regulates cell cycle in CML cells at least in part by inducing
proteasome-mediated degradation of the cell cycle inhibitor
p27Kip1 and provide a rationale for the use of inhibitors of the
proteasome in patients with BCR-ABL leukemias. (Cancer Res
2005; 65(8): 3264-72)
Introduction
Chronic myeloid leukemia (CML) is a hematopoietic stem cell
disease characterized at the molecular level by the expression of
the Philadelphia chromosome translocation that results in the
rearrangement between the breakpoint-cluster region (BCR) on
chromosome 22 and the Abelson leukemia gene (ABL ) on
chromosome 9 (1–3). BCR-ABL encodes a chimeric protein with a
constitutive tyrosine kinase activity. It has been clearly shown that
expression of p210BCR-ABL in hematopoietic cells is essential and
sufficient for malignant transformation (4). BCR-ABL-dependent
kinase activity results in the deregulation of a number of signal
transduction pathways that participate in cell proliferation,
differentiation, migration, adhesion, and apoptosis (3, 5–9).
Expression of BCR-ABL in hematopoietic cells results in growth
factor independence and progression through the G1-S phase of the
cell cycle (10). The mitogenic effects of BCR-ABL require the
activation of the PI3K/Akt pathway that promotes cell survival by
phosphorylation and inactivation of Bad, thus preventing apoptosis
(11). The Ras/Raf/MEK/extracellular signal-regulated kinase path-
way, which is involved in cell cycle regulation, is also altered in
CML (12). Furthermore, we have previously shown that BCR-ABL
also promotes cell survival through STAT5-mediated up-regulation
of Bcl-xL (13).
The development of the BCR-ABL inhibitor STI571 has had an
impact in the treatment of CML patients but has also provided a
new tool for studying the effect of inhibition of the BCR-ABL kinase
activity in cells harboring the endogenous BCR-ABL gene (14).
Initial clinical results in patients with chronic phase CML have
been extremely encouraging with complete cytogenetic remissions
in >40% of patients resistant or refractory to IFN (15). Results in
patients with CML in more advanced phases have not produced
durable responses (16). Newer combinations of STI571 with other
drugs as well as development of other kinase inhibitors are
currently being tested as treatment for CML and Philadelphia
positive acute lymphoblastic leukemia (17).
The cyclin-dependent kinase inhibitor p27Kip1 is a key regulator
of the cell cycle in mammalian cells (18, 19). It negatively regulates
cell cycle progression by directly inhibiting cyclin/Cdk2 complexes.
The activity of p27Kip1 is controlled by its distribution among the
different cell compartments (nucleus and cytoplasm; ref. 20). Akt
directly phosphorylates p27Kip1 at T157 promoting its translocation
to the cytoplasm where it is inactivated (21–23). However, the key
mechanism of regulation of p27Kip1 expression is proteolysis by the
ubiquitin-proteasome pathway (24), mediated by Skp2 containing
SCF complexes. The ubiquitinylation by Skp2 requires the previous
phosphorylation of p27Kip1 at T187 by the same cyclin E/Cdk2
complexes that it inhibits. p27Kip1 is also regulated at the
transcriptional level by transcription factors of the Forkhead/FoxO
family, which are phosphorylated (and inhibited) by Akt (25).
We have previously shown that p27Kip1 plays a significant role in
adhesion-mediated regulation of cell cycle in hematopoietic cells
(26). Recent reports have also suggested a role for the cell cycle
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inhibitor p27Kip1 in the regulation of the cell cycle in BCR-ABL cells
(27–30). In these studies, down-regulation of p27Kip1 has been
shown in human and murine cell lines transfected with BCR-ABL.
However, the mechanism by which BCR-ABL down-regulates
p27Kip1 in primary CML cells or the role of p27Kip1 down-regulation
in the pathogenesis of CML is unclear. Furthermore, analysis of
CD34+ cells from patients with CML has suggested that BCR-ABL–
mediated regulation of p27Kip1 depends on relocation of the cell
cycle inhibitor from the nucleus to the cytoplasm in CML cells,
thus preventing binding to cyclin E/Cdk2 complexes and
promoting cell cycle progression (30).
In the current study, we have examined the role of p27Kip1 in the
pathogenesis of CML. Our results show that BCR-ABL down-
regulates p27Kip1 both by transcriptional regulation and by inducing
proteasome-mediated degradation of the cell cycle inhibitor. The
inhibition of BCR-ABL results in an accumulation of p27Kip1 in the
nucleus and inhibition of cyclin E/Cdk2 kinase activity as well as a
reduction of retinoblastoma phosphorylation. The enhanced
degradation of p27Kip1 is associated with the transcriptional up-
regulation of Skp2 induced by BCR-ABL. Whereas overexpression of
p27Kip1 has no effect on proliferation of BCR-ABL–positive cells, a
T187 p27Kip1 mutant that cannot be recognized by Skp2 induces a
cell cycle arrest, providing evidence for the importance of p27Kip1
degradation in the pathogenesis of CML.
Materials and Methods
Cell lines and primary cells from chronic myeloid leukemia patients
and normal donors. Human-derived Mo7e and Mo7e-p210 cells were
grown in Iscove’s modified Dulbecco’s medium supplemented with 20% fetal
bovine serum, L-glutamine, and penicillin-streptomycin with (Mo7e) or
without (Mo7e-p210) 5 ng/mL of recombinant human interleukin-3 (IL-3).
BaF/3 cells were grown in RPMI supplemented with 10% FCS, L-glutamine
and penicillin-streptomycin, and 10% WEHI-conditioned medium was
added to the culture as a source of murine IL-3 whereas growth of BaF/3-
p210 was independent of growth factors. All media, serum and supplements
were from Invitrogen Life Technologies (Paisley, United Kingdom), except
for human IL-3 (R&D Systems, Minneapolis, MN).
Mobilized peripheral blood or bone marrow mononuclear cells were
obtained from patients in chronic phase CML after informed consent. All
patients were 100% Philadelphia chromosome–positive by direct cytoge-
netic analysis. CD34+ cells from bone marrow or mobilized peripheral blood
were enriched using the MACS CD34+ isolation kit (Miltenyi Biotec,
Cologne, Germany) and either the AutoMACS or the CliniMACS selection
devices as previously described (13). CD34+ purity was always >90% after
positive selection. CD34+ cells were cultured in Iscove’s modified Dulbecco’s
medium supplemented with 20% FBS. IL-3 at a final concentration of 100
ng/mL was also added to the culture medium when the CD34+ cells were
from healthy donors. When indicated, primary cells and/or cell lines were
treated with the tyrosine kinase inhibitor STI571 at a concentration of 2 to
10 Amol/L (generously provided by Dr. Elisabeth Buchdunger, Novartis,
Basel, Switzerland). The PI3K inhibitor LY294002 (Calbiochem, San Diego,
CA) was used at a concentration of 20 Amol/L, the MEK inhibitor PD98059
(Calbiochem) at 30 Amol/L and lactacystin (AFFINITI Research Products,
Ltd., Mamhead, Exeter, United Kingdom) at 10 Amol/L.
Flow cytometry analysis. For cell cycle analysis, 1 to 2  106 cells were
stained with propidium iodide as described (26). Briefly, the cells were
washed twice in cold PBS and fixed in ice-cold 50% ethanol for 30 minutes.
After two more washes in PBS, propidium iodide (Sigma Chemical Co., Poole,
United Kingdom), and RNase A (Sigma) were added to a final concentration
of 100 ng/mL each. After incubation for 1 hour at room temperature, the
cells were kept at 4jC until analysis by flow cytometry (FACScan, Becton
Dickinson, Temse, Belgium) using the CellQuest software.
Western blot analysis, immunoprecipitation, and kinase assays. For
immunoblotting, cell lysates were prepared according to Kabarowski et al.
(31). Protein concentrations were determined with bicinchoninic acid
protein assay (Pierce, Rockford, IL). Cellular proteins (50-100 Ag) were
resolved on SDS-PAGE, transferred to a nitrocellulose membrane (Bio-Rad,
CA), detected with specific antibodies and visualized by enhanced
chemiluminescence (Tropix, Foster City, CA). Antibodies used were from
Santa Cruz Biotechnology (Santa Cruz, CA; ABL, p27Kip1, cyclin E, Cdk2 and
Skp2), BD Biosciences-PharMingen (San Jose, CA; cyclin D, p21Cip1, and
retinoblastoma) and Zymed (South San Francisco, CA; Skp2). Blots were
stripped and reprobed with a h-tubulin antibody (Sigma) as a protein
loading control. Subcellular fractionation of Mo7e-p210 cells cultured in the
presence or absence of STI571 (2 Amol/L) or LY294002 (20 Amol/L) was
done as previously described (32). Protein extracts were quantified with the
Bio-Rad DC Protein Assay and 50 Ag were used for the detection of p27Kip1
in each fraction by Western blot analysis. Lamin A (Cell Signaling, Beverly,
MA) and h-tubulin (Sigma)–specific antibodies were used to assess the
purity of the subcellular fractions. Skp2 was immunoprecipitated with
rabbit polyclonal antibodies (sc-7164, Santa Cruz Biotechnology) and True
Blot anti-rabbit immunoglobulin IP beads (eBioscience, San Diego, CA),
from 1 mg of protein extracts from BaF/3-p210 cells overexpressing Skp2.
Skp2 and p27Kip1 in the immunoprecipitates were detected with mouse
monoclonal antibodies (Santa Cruz Biotechnology) and peroxidase
conjugated anti-mouse IgG-Fc (Pierce).
For kinase assays, cyclin E- or Cdk2-containing complexes were
immunoprecipitated from 150 Ag of protein extracts with 1 Ag of antibody
and 30 AL of Protein A/G-plus Agarose (Santa Cruz Biotechnology). Kinase
activity assays were done as described previously using histone H1 (Roche,
Penzberg, Germany) as substrate (33). The intensity of the bands was
quantified with the QuantityOne software (Bio-Rad).
Quantitative reverse transcription-PCR analysis. Mo7e-p210 cells
were seeded at a density of 25  104 cells/mL and treated with 2 Amol/L
STI571 or 20 Amol/L LY294002. Untreated controls were grown in parallel.
At 24-hour intervals, total RNA was obtained with the RNeasy Mini Kit
(Qiagen, Hilden, Germany), following the manufacturer’s instructions. After
DNase I treatment (amplification grade, Invitrogen), 2 to 5 Ag of total RNA
were used as template for a reverse transcriptase reaction with the
SuperScript First-Strand Synthesis System for reverse transcription-PCR
(Invitrogen), using Oligo(dT) primers. For the relative quantification of the
p27Kip1 and Skp2 mRNA levels, this cDNA was used as template in PCR
reactions in the presence of SYBR Green I (Molecular Probes, Leiden, The
Netherlands) and using the Platinum Taq DNA polymerase (Invitrogen). The
PCR reactions and their analysis were done in an iCycler machine and using
the iCycler iQ Optical System software (Bio-Rad). Besides p27Kip1 and Skp2 ,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also amplified as
an internal control. For the quantification, a standard curve was established
using serial dilutions of a known amount of a plasmid harboring the human
GAPDH cDNA as template for the PCR reactions. Three serial dilutions of
the cDNA from each sample and four replicates of each dilution were used.
The primers used were: p27, D 5V-GCACTGCAGAGACATGGAAG-3V; R 5V-
AGAATCGTCGGTTGCAGGTC-3V; Skp2, D 5V-GCTTCACGTGGGGATGGGAT-
3V; R 5V-GCAGGCCTTCCAGGCTTAGA-3V; GAPDH, D 5V-CATCACCATCTTC-
CAGGAGC-3V; R 5V-CACGGAAGGCCATGCCAG-3V.
Pulse-chase experiment. To examine the turnover of p27Kip1, BaF/3-
p210 cells were incubated with 2 Amol/L STI571 or vehicle for 24 hours and
pulse-labeled for 2 hours with 120 ACi/mL [35S]methionine in methionine-
free MEM medium supplemented with 10% dialyzed FBS. Cells were then
incubated in RPMI containing 10% FBS and excess methionine (chase
medium) for different times. After washing with ice-cold PBS, cell lysates
were prepared in radioimmunoprecipitation assay buffer (1 PBS, 1%
Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L phenyl-
methylsulfonyl fluoride, 0.1 mmol/L leupeptin, 1 mmol/L sodium orthova-
nadate, and 10 mmol/L sodium fluoride). Cellular debris was removed by
centrifugation and the supernatant was subjected to immunoprecipitation
with agarose-conjugated anti-p27Kip1 monoclonal antibodies (Santa Cruz
Biotechnology). Immune complexes were washed five times with radio-
immunoprecipitation assay buffer and the eluted proteins were analyzed by
SDS-gel electrophoresis on 12% acrylamide gels. The labeled p27Kip1 protein
was detected by fluorography and quantified with the QuantityOne software
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(Bio-Rad). p27Kip1 degradation rates were calculated from the slope of the
logarithmic transformation of the densitometry data plotted against time,
as previously described (34).
Retroviral infections. Wild-type p27Kip1 and two different mutants,
p27P- (mutated at Thr187 and therefore unable to be phosphorylated and
degraded) and p27ck- (unable to interact with neither cyclin nor Cdk; ref. 35)
were introduced in BaF/3-p210 cells using the LZRS-IRES-green fluorescent
protein retroviral vector (36). Replication-defective retroviruses were
produced by transfecting Bosc 23 producer cells with the recombinant
DNAs. BaF/3-p210 cells (at a density of 2  106 cells/mL) were incubated for
3 hours with 4 mL of filtered supernatant from producer cells in the
presence of 8 Ag/mL polybrene (Sigma). The day after infection, cells were
seeded at 400  103 cells/mL. Green fluorescent protein expression was
used to detect infected cells by fluorescence microscopy.
Adenoviral infections. The AdEasy adenovirus system (37) was used to
overexpress Skp2 in BaF/3-p210 cells. The Skp2 adenovirus was a kind gift
from Dr. D. Wolf and was described previously (38). Silencing of Skp2
expression in BaF/3-p210 was achieved by infection with AdEasy-derived
adenovirus harboring the H1 promoter from pSUPER (39) to generate small
interfering RNA. The sequence of the Skp2 small interfering RNA was 5V-
AAGGGAGTGACAAAGACTTTG-3V(40). Cells were infected as described (41),
with a multiplicity of infection of 1,000. Briefly, adenovirus produced in 293
cells were mixed with 50 103 Ag Superfect (Qiagen) for 10 minutes before
their addition to 1  106 BaF/3-p210 cells. The cells were incubated with the
adenovirus for 6 hours and then the medium was changed. Flow cytometry
analysis of green fluorescent protein–positive cells gave an infection rate of
15% to 20%. Cell extracts were prepared 72 hours after the infection.
Results
STI571 induced cell cycle arrest in BCR-ABL cells is
associated with an accumulation of the cell cycle inhibitor
p27Kip1. We initially examined the effect of STI571 on the
proliferation of BCR-ABL cells. Incubation with STI571 inhibited
the proliferation of Mo7e-p210 and BaF/3-p210 cells, but had no
effect on the proliferation of wild-type Mo7e or BaF/3 cells (Fig. 1A ,
top). Mo7e-p210 and BaF/3-p210 cells express the protein BCR-ABL
p210, whereas only ABL can be detected in their wild-type controls
by Western blotting (Fig. 1A , bottom). Cell cycle analysis indicated
that STI571 induces a G1 arrest in BCR-ABL–positive cells, with a
reduction in the proliferating population (S + G2-M phases) from
35% to 5% in Mo7e-p210 cells and from 33% to 15% in BaF/3-p210
cells (Fig. 1B). Similar results were observed in CD34+ cells
obtained from patients with CML in chronic phase (34 to 6%
reduction in the percentage of proliferating cells), whereas no
significant changes were found in control CD34+ cells (Fig. 1B). As
we have previously described (13), STI571 induced an increase in
apoptosis in BCR-ABL–positive cells (Fig. 1B).
To determine potential mechanisms involved in abnormal
proliferation of BCR-ABL–positive cells we examined the expres-
sion of proteins that participate in the regulation of the cell cycle.
Inhibition of BCR-ABL kinase activity was associated with an
increase in the protein levels of the cell cycle inhibitor p27Kip1 and
a decrease in p21Cip1, cyclin E, and cyclin D protein levels in Mo7e-
p210 cells, whereas there was no effect in the parental wild-type
Mo7e cells (Fig. 1C). Similar changes were observed in BaF/3-p210
cells, although the reduction in the levels of the cyclins was less
evident. When we examined the effect of STI571 on chronic phase
CML and normal human CD34+ cells, we could show that similar
to the Mo7e-p210 cells, inhibition of BCR-ABL was associated with
an accumulation of p27Kip1 and a reduction of cyclin D and cyclin E
proteins (Fig. 1D). We could not detect the expression of p21Cip1 in
normal or CML CD34+ cells.
STI571 inhibition of BCR-ABL results in the underphos-
phorylation of retinoblastoma. The changes in the protein levels
seen when we treated BCR-ABL–positive cells with STI571,
specially the accumulation of p27Kip1, suggests that the blockage
of the cell cycle in the G1 phase could be the result of an inhibition
in the Cdk-dependent kinase activity responsible for the phos-
phorylation of retinoblastoma. To test this hypothesis, we analyzed
the localization of p27Kip1 in Mo7e-p210 cells treated with STI571
for 9 hours. As shown in Fig. 2A , treatment with STI571 induced a
marked increase in the amount of p27Kip1 in the nuclear fraction.
This accumulation of p27Kip1 was associated with a 60% decrease
in the cyclin E/Cdk2 kinase activity in the presence of STI571 in
Mo7e-p210 in comparison with Mo7e-wt cells (Fig. 2B). Further-
more, treatment with STI571 results in a reduction of retinoblas-
toma phosphorylation in Mo7e-p210 and primary CML CD34+ cells
but not in Mo7e-wt or normal CD34+ cells, as shown by Western
blotting (Fig. 2C). These results suggest that STI571-mediated BCR-
ABL-dependent cell cycle arrest is associated with a reduction in
the phosphorylation status of retinoblastoma due to the inhibition
of Cdk kinase activity by p27Kip1.
The PI3K pathway mediates the effect of BCR-ABL on the
cell cycle. BCR-ABL regulates the activity of two main signal
transduction pathways involved in survival and proliferation, the
PI3K/Akt and the Ras/Raf/MEK pathways. We wanted to know
which of these two was the one by which the expression of p27Kip1
is regulated in BCR-ABL cells. We treated Mo7e-p210 and BaF/3-
p210 cells with an inhibitor of PI3K (LY294002) or with an inhibitor
of MEK (PD98059) and studied their effect on cell proliferation. As
shown in Fig. 3A , inhibition of MEK with PD98059 had no effect
on proliferation, whereas inhibition of PI3K with LY294002 blocked
proliferation of both cell lines, suggesting that BCR-ABL-induced
proliferation is mediated mainly by the PI3K/Akt pathway.
Furthermore, inhibition of the PI3K pathway with LY294002 results
in an accumulation of p27Kip1 in Mo7e-p210 and in BaF/3-p210
cells (Fig. 3B). Similar to the effect seen after inhibition of BCR-
ABL kinase activity with STI571, the p27Kip1 protein accumulates
mainly in the nuclear fraction of Mo7e-p210 cells (Fig. 3C).
BCR-ABL regulates the levels of p27Kip1 by transcription
inhibition and induced degradation. We next studied the
mechanisms by which BCR-ABL activity reduces the levels of
p27Kip1. p27Kip1 expression may be regulated both at the
transcriptional level by the FoxO transcription factors or by
proteasome-mediated degradation following ubiquitinylation. In
order to determine which mechanism is altered in BCR-ABL cells,
we did two types of experiments. Firstly, we treated Mo7e-p210
cells with STI571 or LY294002 and extracted the RNA at different
time points. We analyzed the amount of p27Kip1 mRNA by
quantitative reverse transcription-PCR using GAPDH as an
internal control. As shown in Fig. 4, there was an increase in the
levels of p27Kip1 mRNA when we treated the cells with either
STI571 or LY294002, suggesting that BCR-ABL inhibits the
transcription of the p27Kip1 gene through the PI3K pathway.
Secondly, we did a pulse-chase experiment to determine the
degradation rate of the p27Kip1 protein in BaF/3-p210 cells. Incubation
of the cells with STI571 resulted in a time-dependent accumulation of
labeled p27Kip1 in comparison with untreated BaF/3-p210 cells (Fig.
4B). Densitometric analysis of the bands (Fig. 4C) revealed that the
degradation rate of p27Kip1, calculated from the slope of the
logarithmic transformation of the densitometry data plotted against
time, is slower when BCR-ABL kinase activity is inhibited by STI571,
meaning that BCR-ABL increases the degradation of p27Kip1.
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Analysis of the data with a t test revealed that the slopes of the two
lines (0.0328 for the STI treatment and 0.0566 for control) are
significantly different from each other (P < 0.01). The inhibition of
the proteasome with 10 Amol/L lactacystin also resulted in an
increment of p27Kip1 stability (data not shown), confirming that the
degradation of p27Kip1 depends on the proteasome activity.
Skp2 is involved in the degradation of p27Kip1 and its
expression is induced by BCR-ABL. It has been shown that the
degradation of p27Kip1 in the proteasome requires its phosphor-
ylation at T187 followed by its ubiquitinylation by the SCFSkp2
complex. We wanted to know whether Skp2 could also be the F-
box protein involved in the degradation of p27Kip1 in our cell
system. Silencing the expression of Skp2 with adenovirus-
produced small interfering RNA resulted in an accumulation of
p27Kip1 in BaF/3-p210 cells, whereas the overproduction of Skp2
resulted in a decrease of this protein (Fig. 5A , top). In Skp2
Figure 1. STI571 treatment blocks proliferation of BCR-ABL cells in G1. A, Mo7e-wt, Mo7e-p210, BaF/3-wt, and BaF/3-p210 cells were treated with
2 Amol/L STI571 (STI ) or vehicle (C ) and maintained in culture for 4 days. Viable cells (determined by trypan blue exclusion) were counted daily. The results
represent the mean and SE of three independent experiments. Bottom, expression of BCR-ABL detected by Western blotting with an anti-ABL antibody in BaF/3-wt,
BaF/3-p210, Mo7e-wt and Mo7e-p210 cell extracts; B, Mo7e-p210, BaF/3-p210, normal human CD34+ and chronic phase CML–derived CD34+ cells were
incubated with 2 Amol/L STI571 or vehicle (Control ) for 24 hours and then the cell cycle profile was analyzed by flow cytometry as described in Materials and Methods.
A representative example of three different experiments is shown. In each graph, the percentage of cells in the S + G2-M phases is shown; C, Mo7e-p210,
Mo7e-wt, BaF/3-p210, and BaF/3-wt cells were incubated with 2 Amol/L STI571. Cells were harvested, washed and lysed at the times indicated as described in
Materials and Methods. Protein extracts (50 Ag) were separated by SDS-PAGE and electrotransferred onto nitrocellulose membranes. Different blots with the same
samples were probed with the indicated antibodies; D, CD34+ cells from patients with chronic phase CML or normal donors were incubated with 2 Amol/L STI571.
At the times indicated, cells were harvested, washed and lysed. A total of 50 Ag of protein extract were separated by SDS-PAGE and probed with the indicated
antibodies. Representative examples of three independent experiments are shown.
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overexpressing BaF/3-p210 cells, we could coimmunoprecipitate
Skp2 and p27Kip1 (Fig. 5A , bottom), showing a direct interaction
between these two proteins. We then explored whether the
expression of Skp2 was dependent on BCR-ABL activity. We
treated Mo7e-p210 and BaF/3-p210 cells with STI571 or LY294002
and analyzed the expression of Skp2 by Western blotting. As
shown in Fig. 5B , both treatments resulted in a reduction of the
Skp2 protein levels 24 hours after the treatment, suggesting that
BCR-ABL signals through the PI3K pathway to induce the
expression of Skp2. When we examined the effect of STI571 on
chronic phase CML and normal human CD34+ cells, we could
show that similar to the cell lines, inhibition of BCR-ABL was
associated with a decrease in the expression of Skp2 (Fig. 5C).
Moreover, analysis by quantitative reverse transcription-PCR showed
that there is a reduction in the Skp2 mRNA levels when Mo7e-p210
cells are treated with either STI571 or LY294002 (Fig. 5D). In
summary, these results indicate that the BCR-ABL/PI3K pathway
regulates the expression of Skp2 at least at the level of
transcription.
Expression of a T187V p27Kip1 mutant induces a cell cycle
arrest in BCR-ABL–positive cells. Thus far, our results show that
the inhibition of BCR-ABL induces a cell cycle arrest that is
accompanied by an increase in the p27Kip1 protein levels that
results from transcriptional induction and inhibition of degrada-
tion mediated by Skp2 activity. To determine to what extent
p27Kip1 degradation is responsible for the increased proliferation of
BCR-ABL–positive cells, we infected BaF/3-p210 cells with LZRS-
IRES-green fluorescent protein–derived retroviruses expressing
wild-type p27Kip1 or the T187V mutant, which cannot be
phosphorylated by Cdk-containing complexes and therefore is
not ubiquitinylated by SCFSkp2 nor degraded at the proteasome
(35). As shown in Fig. 6, cells expressing wild-type p27Kip1 kept
proliferating as well as the uninfected cells, cells infected with the
Figure 2. STI571-treated cells accumulate p27Kip1 in the nucleus and show a
decrease in cyclin E/Cdk2 kinase activity. A, Mo7e-p210 cells were incubated
with 2 Amol/L STI571 or vehicle (Control ) for 9 hours and processed as
described in Materials and Methods to separate the nuclear (N ) and cytoplasmic
(C) fractions. Extracts were separated by SDS-PAGE and probed with the
indicated antibodies. Lamin and h-tubulin are markers for the nuclear and
cytoplasmic fractions, respectively; B, Mo7e-p210 and Mo7e-wt cells were
treated with 2 Amol/L STI571 for the indicated times. Protein extracts (150 Ag)
were incubated with antibodies against cyclin E or Cdk2 as indicated and kinase
activity of the immunoprecipitated complexes was assayed as described in
Materials and Methods. Reaction products were resolved by SDS-PAGE and the
phosphorylated substrate (histone H1 ) was detected by exposing the dried gels
to X-ray films. The numbers below each band represent the intensity of the
bands relative to time 0; C, Mo7e-p210, Mo7e-wt, and CD34+ cells from normal
donors and CML patients were treated with 2 Amol/L STI571 for 24 and 48 hours
and 50 Ag of cell lysates were separated by SDS-PAGE, electrotransferred, and
incubated with antibodies against total retinoblastoma protein or h-tubulin as a
loading control. The fast migrating bands represent the underphosphorylated
form of retinoblastoma, whereas the slow migrating bands correspond to
hyperphosphorylated retinoblastoma. A representative example of three
independent experiments is shown.
Figure 3. The PI3K pathway mediates the effect of BCR-ABL on cell
proliferation and on p27Kip1 accumulation. A, Mo7e-p210 (M-p210 ) and
BaF/3-p210 (B-p210 ) cells were treated with 20 Amol/L LY294002 (LY),
30 Amol/L PD98059 (PD ) or vehicle (C ) and maintained in culture for 4 days.
Viable cells (determined by trypan blue exclusion) were counted daily. The
results represent the mean and SE of three independent experiments; B,
Mo7e-p210 and BaF/3-p210 cells were cultured in the presence of 20 Amol/L
LY294002. At the times indicated, cells were harvested and cell extracts were
prepared and analyzed by Western blotting as described in Materials and
Methods. A representative example of three different experiments is shown; C,
Mo7e-p210 cells were incubated with 20 Amol/L LY294002 (LY ) or vehicle
(Control) for 48 hours and processed as described in Materials and Methods to
separate the nuclear (N ) and cytoplasmic (C ) fractions. Extracts were separated
by SDS-PAGE and probed with the indicated antibodies. Lamin and h-tubulin
are markers for the nuclear and cytoplasmic fractions, respectively.
Cancer Research
Cancer Res 2005; 65: (8). April 15, 2005 3268 www.aacrjournals.org
 American Association for Cancer Research Copyright © 2005 
 on May 11, 2011cancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/0008-5472.CAN-04-1357
empty retrovirus (vector), or cells infected with a p27Kip1 mutant
unable to interact with either cyclin or Cdk (p27 ck). However,
expression of the undegradable mutant of p27Kip1 (p27 P)
inhibited proliferation of BCR-ABL cells (Fig. 6). This result
confirms that the degradation of p27Kip1 is necessary for the
induction of cell proliferation by BCR-ABL.
Discussion
The main findings of our study pertain to the mechanism of BCR-
ABL–mediated regulation of the cell cycle: by inhibiting the tyrosine
kinase activity of the oncogene, we show that proliferation of CML
cells depends on BCR-ABL–mediated proteasome-dependent deg-
radation of p27Kip1, which is associated with increased levels of
cyclins D and E and phosphorylation of retinoblastoma. Secondly,
degradation of p27Kip1 is necessary for cell cycle progression in CML
cells as shown by the fact that a nondegradable mutant of p27Kip1
blocks cell cycle proliferation on BCR-ABL–positive cells. There is
an inverse regulation of the levels of p27Kip1 and Skp2 in BCR-ABL
cells that is mediated by the PI3K pathway. More importantly, these
results are observed not only on BCR-ABL cell lines but also on
samples from patients with CML in chronic phase.
Recent studies have suggested a role for p27Kip1 in cell cycle
regulation in BCR-ABL–positive cells (27–30). Most of these studies
have used different models of BCR-ABL cell lines and have
consistently suggested that inhibition of the BCR-ABL kinase
activity is associated with cell cycle inhibition, increased p27Kip1
protein levels and decreased cyclin D expression (27–29). Our
results have also extended these observations in both cell lines and
primary CML cells demonstrating the mechanism involved in BCR-
ABL–mediated regulation of p27Kip1 and their causal relation with
cell cycle deregulation in CML.
Unlike p27Kip1 levels, inhibition of BCR-ABL was associated with
a decreased expression of the cell cycle inhibitor p21Cip1.
Discordant expression of p27Kip1 and p21Cip1 has been previously
described in other models of proliferating cells in which
proliferation depends on the assembly between p21Cip1 and cyclin
D-Cdk4 (42, 43), and BCR-ABL expression has also been associated
with up-regulation of p21Cip1 (27).
Jiang et al. (30) have recently shown that levels of p27Kip1 are
significantly higher in primary CML CD34+ cells versus normal
CD34+ cells. However, p27Kip1 is not able to bind and inactivate
Cdk2 kinase activity nor affect changes in cyclin E or cyclin D levels
due to relocation of the protein to the cytoplasm instead of the
nucleus. Differences in the in vitro models might explain some of
the discrepancies between that work and our results. We compared
the levels of p27Kip1 in CML cells before, 24, and 48 hours after
inhibition of BCR-ABL activity with STI571, instead of normal
versus CML cells. Furthermore, Jiang et al.’s studies were planned
to assess the effect of h1-integrin-mediated adhesion on cell cycle
in CML cells in comparison with normal CD34+ cells, whereas our
studies were always done using a nonadherent system. In any case,
we have also observed that BCR-ABL induces an abnormal
localization of p27Kip1 as treatment with STI571 induces relocal-
ization of p27Kip1 to the nucleus.
The decrease in the p27Kip1 protein levels that we see in BCR-
ABL cells is also due to a regulation at the transcriptional level.
p27Kip1 gene transcription is up-regulated by the Forkhead/FoxO
transcription factors (25), which in turn are phosphorylated and
inactivated by Akt (44). By activating the PI3K/Akt pathway, BCR-
ABL is inhibiting transcription of the p27Kip1 gene, as we see in our
quantitative reverse transcription-PCR experiments using inhib-
itors of both BCR-ABL and PI3K. This is in agreement with results
from Komatsu et al. (45) showing that BCR-ABL controls the
expression of p27Kip1 through the Akt-dependent phosphorylation
of FKHRL1/FoxO3a.
Several recent reports indicate that BCR-ABL participates in the
regulation of the proteasome by increasing the proteasome-
mediated degradation of a number of proteins (46–48). Indirect
evidence also indicates that p27Kip1 is regulated by proteasome-
mediated degradation in BCR-ABL–positive cells (27, 28). Our
results show that BCR-ABL–mediated regulation of p27Kip1 is
indeed dependent on proteasome degradation. The degradation of
Figure 4. BCR-ABL regulates the transcription and the degradation of p27Kip1.
A, Mo7e-p210 cells were treated with 2 Amol/L STI571, 20 Amol/L LY294002
or untreated (Control). At the indicated times, total RNA was extracted
and the amount of p27Kip1 mRNA was analyzed by quantitative reverse
transcription-PCR as described in Materials and Methods. Columns, mean; bars,
SE of the amount of p27Kip1 mRNA relative to that of GAPDH and referred to
time 0 of three independent experiments; B, BaF/3-p210 cells were incubated
in the absence (Control ) or presence of 2 Amol/L STI571 for 24 hours and
metabolically labeled with [35S]methionine and chased for the times indicated
as described in Materials and Methods. Extracts from an equal number of cells
were immunoprecipitated with agarose-conjugated anti-p27Kip1 antibodies and
the radiolabeled immunoprecipitated p27Kip1 protein was resolved by SDS-PAGE
and visualized by fluorography. Results from one representative experiment
are shown; C, the intensity of the bands from four independent pulse-chase
experiments done as described in (B ) was quantified using the QuantityOne
software (Bio-Rad) and the logarithmic transformation of the intensity relative
to the zero time point F SD was plotted against time.
Regulation of Skp2 and p27 Kip1 in CML Cells
www.aacrjournals.org 3269 Cancer Res 2005; 65: (8). April 15, 2005
 American Association for Cancer Research Copyright © 2005 
 on May 11, 2011cancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/0008-5472.CAN-04-1357
p27Kip1 is specific and not due to an enhanced activity of the
proteasome, because the levels of other cell cycle regulatory
proteins (like cyclin E), which are also degraded by the proteasome,
are reduced upon inhibition of BCR-ABL. p27Kip1 degradation is
mediated by the F-box protein Skp2, a component of the E3
ubiquitin ligase SCF complex (49). It has been shown that the levels
of Skp2 are up-regulated by PI3K (50). We have shown that BCR-
ABL-induced degradation of p27Kip1 is associated with increased
levels of the Skp2 protein related to activation of the PI3K
pathway. This regulation is at the level of transcription, although
we still do not know which transcription factor may be involved.
Based on these results as well as the fact that the expression of a
p27Kip1 mutant, unable of being phosphorylated in T187 and
therefore unable of being recognized by Skp2 and degraded,
blocks cell cycle progression, proteasome inhibitors such as PS-
341 or other new molecules may be useful drugs for treatment of
BCR-ABL harboring diseases (51, 52). Furthermore, it has
recently been shown that resistance to STI571 can arise as a
consequence of point mutations in BCR-ABL that prevents
STI571 from inhibiting the kinase activity of the oncoprotein.
Inhibition of the proteasome or even of the PI3K pathway by
inhibitors such as LY294002 could be a means to overcome these
resistances (53).
Figure 5. Interaction between Skp2 and p27Kip1 and regulation of the
expression of Skp2 by STI571 or LY294002 treatment. A, functional and
physical interaction between Skp2 and p27Kip1 in BCR-ABL cells. BaF/3-p210
cells were infected with adenovirus producing a small interfering RNA (si )
to silence the expression of Skp2, infected with adenovirus expressing Skp2
(Skp2 ), or left uninfected (C ) and the expression of Skp2 and p27Kip1
was analyzed by Western blotting (top ). Protein extracts from BaF/3-p210
cells infected with adenovirus expressing Skp2 were immunoprecipitated with
polyclonal antibodies against Skp2 and anti-rabbit immunoglobulin IP beads
(IP ) or with anti-rabbit immunoglobulin IP beads alone (C ) and the presence
of Skp2 and p27Kip1 in the immunoprecipitates was analyzed by Western blotting
with monoclonal antibodies (bottom ); B, Mo7e-p210 (top ) and BaF/3-p210
(bottom ) cells were treated with 2 Amol/L STI571 or 20 Amol/L LY294002. At the
indicated times, cells were harvested and lysed as described in Materials and
Methods. Cell extracts (50 Ag) were separated by SDS-PAGE, electrotransferred
and probed with antibodies against Skp2 or h-tubulin as a loading control.
A representative example of three independent experiments is shown; C, CD34+
cells from normal donors or CML patients were cultured in the presence of
2 Amol/L STI571. At the times indicated, 50 Ag of cell lysates were separated
by SDS-PAGE, electrotransferred, and incubated with antibodies against Skp2
or h-tubulin. A representative example of three independent experiments is
shown; D, Mo7e-p210 cells were treated with 2 Amol/L STI571, 20 Amol/L
LY294002, or untreated (Control ). At the indicated times, total RNA
was extracted and the amount of Skp2 mRNA was analyzed by quantitative
reverse transcription-PCR as described in Materials and Methods. Columns,
mean; bars, SE of Skp2 mRNA relative to that of GAPDH and referred to
time 0 of three independent experiments.
Figure 6. Expression of the T187V p27Kip1 mutant but not wild-type p27Kip1
blocks proliferation of BCR-ABL cells. BaF/3-p210 cells were infected with the
empty LZRS-IRES-green fluorescent protein retrovirus (Vector) or derived
retroviruses expressing either wild-type p27Kip1, the T187V p27Kip1 mutant (P )
or an inactive p27Kip1 mutant (ck). See text for an explanation of the different
mutants. Two days after infection, cells were seeded at the same density
(day 0) and infected cells (green fluorescent protein–positive cells) were counted
using a fluorescence microscope for 3 more days. In each case, cell numbers
were normalized using the number of green fluorescent protein–positive
cells at day 0 as a reference. Points, mean; bars, SE of six independent
experiments.
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Therefore, p27Kip1 is a major target of BCR-ABL to promote
proliferation. There are three ways in which the levels and activity
of p27Kip1 are regulated in CML cells: first, BCR-ABL induces a
relocalization of p27Kip1 to the cytoplasm where it is inactive;
second, BCR-ABL inhibits p27Kip1 gene transcription by affecting,
presumably, the activity of the transcription factors of the
Forkhead/FoxO family; and third, BCR-ABL induces p27Kip1
degradation by increasing the levels of Skp2 protein. All these
effects are mediated by the PI3K pathway. Recently, it has been
shown that this pathway regulates the localization of p27Kip1 and
its transcription in HL60 leukemia cells (54), but ours is the first
report in which we are able to show that BCR-ABL is affecting all
three mechanisms and not only in cell lines but also in primary
cells from CML patients.
In conclusion, our results provide new insights into the
mechanism of BCR-ABL–mediated regulation of the cell cycle
and pave the way for the use of new drugs such as proteasome
inhibitors in the treatment of patients with CML. Combinations of
currently effective therapies such as STI571 with new compounds
such as PS-341 may further improve the expectations of patients
and indicate new alternatives in patients that have developed
resistance to STI571.
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